Jun 28, 2025, 15:25

DoD FY25 Prostate Cancer Research Program Idea Development Award

Supports innovative, high‐risk/high‐reward research ideas in prostate cancer that address one or more FY25 PCRP Overarching Challenges. Two application categories—Established Investigator and New Investigator—foster novel approaches with or without preliminary data.

Eligibility Criteria:

Applicant Organizations: Extramural and intramural entities (academic institutions, biotech companies, foundations, DOD labs, etc.), for-profit and non-profit, U.S. or foreign .
Principal Investigator:
- Established Investigator: Independent investigator at any faculty rank by award activation.
- New Investigator: Within 10 years of terminal degree completion, freedom to pursue independent research goals without formal mentorship, and must identify a collaborator experienced in prostate cancer research .
Human Subjects: Observational clinical research permitted; interventional clinical trials excluded.
Cost Sharing: Not required.

Funding Details:

Total Available: ~30.5 M USD across both categories
- Established Investigator: 22.1 M USD to fund ~13 awards, up to 1.7 M USD total costs over 3 years .
- New Investigator: 8.4 M USD to fund ~4 awards, up to 2.1 M USD total costs over 4 years .
Allowable Costs: Direct and indirect costs per negotiated rates; personnel, supplies, equipment, limited travel; no clinical trial costs.
Award Activation: No later than September 30, 2026; funds expire September 30, 2031.

Deadline:

Letter of Intent: August 8, 2025, by 5:00 p.m. ET
Full Application: August 29, 2025, by 11:59 p.m. ET
Verification Period Ends: September 3, 2025, by 5:00 p.m. ET
Peer Review: October 2025
Programmatic Review: February 2026

Where to Go for Further Information:

Download the Program Announcement

eBRAP Portal
Grants.gov Workspace: search FOA HT942525PCRPIDA

cancer CDMRP DoD eBRAP established-investigator Funding opportunity high-risk research idea-development-award new-investigator OncoDaily Oncology PCRP prostate cancer translational research

25 Posts Not To Miss From ESMO GI 2025

Botensilimab and Balstilimab Show Durable Survival in MSS Colorectal Cancer: ESMO GI 2025 Update

Julian McMahon Dies at 56: A Look Back at His Private Cancer Battle and Legendary Acting Career

Vivek Subbiah: It’s Time We Evolve WHO Cancer Classification

ESMO 50th Anniversary: Half a Century of Evidence-Based Cancer Care